Skip to main content
Erschienen in: Endocrine 1/2020

20.02.2020 | Original Article

Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission

verfasst von: Marcelo Lemos Vieira da Cunha, Luis Alencar Biurrum Borba, Cesar Luiz Boguszewski

Erschienen in: Endocrine | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the role of IGF-I and random GH measurements 3 months after transsphenoidal surgery (TSS) in predicting long-term remission in acromegaly patients.

Methods

Retrospective analysis of 54 acromegaly patients who underwent TSS with the same neurosurgery team. Random GH and IGF-I values evaluated 3 months after TSS were related to long-term outcomes. The initiation of adjuvant therapy at any time defined surgical failure.

Results

At 3 months, 14 (25.9%) patients had controlled disease (CD; normal IGF-I and GH < 1.0 µg/L), 25 (46.3%) had uncontrolled disease (UD; high IGF-I and GH), and 15 (27.8%) had biochemical discrepancies (BD): 12 BDI (normal IGF-I + GH ≥ 1.0 μg/L) and 3 BDII (high IGF-I + GH < 1.0 μg/L). All patients of the CD group, 2 of the UD, 11 of the BDI, and 2 of the BDII, progressed with long-term remission and had IGF-I ≤ 1.25-fold the Upper Limit of Normal (ULN), in contrast with all cases of surgical failure where IGF-I was ≥1.3-fold ULN. Only one patient with normal IGF-I had recurrence, resulting in 100% sensitivity and 96% specificity of post-surgical IGF-I ≤ 1.25-fold ULN to predict long-term remission, observed in 54% of our cohort. Post-surgical random GH ≥ 1.7 µg/L was the best cutoff to identify surgical failure, but its accuracy to predict long-term outcomes was limited.

Conclusions

IGF-I levels ≤ 1.25-fold ULN 3 months after TSS was the best guide for long-term remission in acromegaly patients with both initial surgical failure and discrepant biochemical results.
Literatur
1.
Zurück zum Zitat C. Beauregard, U. Truong, J. Hardy, O. Serri, Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin. Endocrinol. 58(1), 86–91 (2003)CrossRef C. Beauregard, U. Truong, J. Hardy, O. Serri, Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin. Endocrinol. 58(1), 86–91 (2003)CrossRef
5.
Zurück zum Zitat R.M. Starke, D.M. Raper, S.C. Payne, M.L. Vance, E.H. Oldfield, J.A. Jane Jr, Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J. Clin. Endocrinol. Metab. 98(8), 3190–3198 (2013). https://doi.org/10.1210/jc.2013-1036 CrossRefPubMed R.M. Starke, D.M. Raper, S.C. Payne, M.L. Vance, E.H. Oldfield, J.A. Jane Jr, Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J. Clin. Endocrinol. Metab. 98(8), 3190–3198 (2013). https://​doi.​org/​10.​1210/​jc.​2013-1036 CrossRefPubMed
10.
Zurück zum Zitat E. Sala, E. Ferrante, M. Locatelli, P. Rampini, G. Mantovani, C. Giavoli, M. Filopanti, E. Verrua, E. Malchiodi, G. Carrabba, M. Arosio, P. Beck-Peccoz, A. Spada, A.G. Lania, Diagnostic features and outcome of surgical therapy of acromegalic patients: experience of the last three decades. Hormones 13(1), 95–103 (2014)CrossRefPubMed E. Sala, E. Ferrante, M. Locatelli, P. Rampini, G. Mantovani, C. Giavoli, M. Filopanti, E. Verrua, E. Malchiodi, G. Carrabba, M. Arosio, P. Beck-Peccoz, A. Spada, A.G. Lania, Diagnostic features and outcome of surgical therapy of acromegalic patients: experience of the last three decades. Hormones 13(1), 95–103 (2014)CrossRefPubMed
14.
Zurück zum Zitat S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina,Acromegaly Consensus Group, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009). https://doi.org/10.1210/jc.2008-2421 CrossRefPubMed S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina,Acromegaly Consensus Group, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009). https://​doi.​org/​10.​1210/​jc.​2008-2421 CrossRefPubMed
15.
Zurück zum Zitat A. Boeving, L.A. Borba, A.M. Rodrigues, E.B. Orichowski, G.J. Paz Filho, C.M. Santos, C.L. Boguszewski, Outcome of surgical treatment for acromegaly performed by a single neurosurgeon and cumulative meta-analysis. Arq. Bras. Endocrinol. Metab. 50(5), 884–892 (2006)CrossRef A. Boeving, L.A. Borba, A.M. Rodrigues, E.B. Orichowski, G.J. Paz Filho, C.M. Santos, C.L. Boguszewski, Outcome of surgical treatment for acromegaly performed by a single neurosurgeon and cumulative meta-analysis. Arq. Bras. Endocrinol. Metab. 50(5), 884–892 (2006)CrossRef
16.
Zurück zum Zitat E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610–617 (1993). discussion 617–618PubMed E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610–617 (1993). discussion 617–618PubMed
22.
Zurück zum Zitat I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89(2), 667–674 (2004)CrossRefPubMed I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89(2), 667–674 (2004)CrossRefPubMed
23.
Zurück zum Zitat L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller,American Association of Clinical Endocrinologists, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr. Pract. 17(Suppl 4), 1–44 (2011)CrossRefPubMed L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller,American Association of Clinical Endocrinologists, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr. Pract. 17(Suppl 4), 1–44 (2011)CrossRefPubMed
25.
Zurück zum Zitat K. Schilbach, C.J. Strasburger, M. Bidlingmaier, Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 20(1), 33–45 (2017)CrossRefPubMed K. Schilbach, C.J. Strasburger, M. Bidlingmaier, Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 20(1), 33–45 (2017)CrossRefPubMed
27.
Zurück zum Zitat A.L. Espinosa-de-Los-Monteros, E. Sosa, S. Cheng, R. Ochoa, C. Sandoval, G. Guinto, V. Mendoza, I. Hernandez, M. Molina, M. Mercado, Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin. Endocrinol. 64(3), 245–249 (2006). https://doi.org/10.1111/j.1365-2265.2006.02430.x CrossRef A.L. Espinosa-de-Los-Monteros, E. Sosa, S. Cheng, R. Ochoa, C. Sandoval, G. Guinto, V. Mendoza, I. Hernandez, M. Molina, M. Mercado, Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin. Endocrinol. 64(3), 245–249 (2006). https://​doi.​org/​10.​1111/​j.​1365-2265.​2006.​02430.​x CrossRef
29.
Zurück zum Zitat A. Muhammad, E.C. Coopmans, P.J.D. Delhanty, A.H.G. Dallenga, I.K. Haitsma, J.A.M.J.L. Janssen, A.J. van der Lely, S.J.C.M.M. Neggers, Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur. J. Endocrinol. 179(5), 269–277 (2018). https://doi.org/10.1530/EJE-18-0353 CrossRefPubMed A. Muhammad, E.C. Coopmans, P.J.D. Delhanty, A.H.G. Dallenga, I.K. Haitsma, J.A.M.J.L. Janssen, A.J. van der Lely, S.J.C.M.M. Neggers, Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur. J. Endocrinol. 179(5), 269–277 (2018). https://​doi.​org/​10.​1530/​EJE-18-0353 CrossRefPubMed
31.
Zurück zum Zitat S. Ahmed, M. Elsheikh, I.M. Stratton, R.C. Page, C.B. Adams, J.A. Wass, Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin. Endocrinol. 50(5), 561–567 (1999)CrossRef S. Ahmed, M. Elsheikh, I.M. Stratton, R.C. Page, C.B. Adams, J.A. Wass, Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin. Endocrinol. 50(5), 561–567 (1999)CrossRef
32.
Zurück zum Zitat I. Shimon, Z.R. Cohen, Z. Ram, M. Hadani, Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48(6), 1239–1243 (2001). discussion 1244–1235PubMed I. Shimon, Z.R. Cohen, Z. Ram, M. Hadani, Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48(6), 1239–1243 (2001). discussion 1244–1235PubMed
36.
Zurück zum Zitat C.C. van Bunderen, N.C. van Varsseveld, J.C. Baayen, W.R. van Furth, E.S. Aliaga, M.J. Hazewinkel, C.B. Majoie, N.J. Freling, P. Lips, E. Fliers, P.H. Bisschop, M.L. Drent, Predictors of endoscopic transsphenoidal surgery outcome in acromegaly: patient and tumor characteristics evaluated by magnetic resonance imaging. Pituitary 16(2), 158–167 (2013). https://doi.org/10.1007/s11102-012-0395-7 CrossRefPubMed C.C. van Bunderen, N.C. van Varsseveld, J.C. Baayen, W.R. van Furth, E.S. Aliaga, M.J. Hazewinkel, C.B. Majoie, N.J. Freling, P. Lips, E. Fliers, P.H. Bisschop, M.L. Drent, Predictors of endoscopic transsphenoidal surgery outcome in acromegaly: patient and tumor characteristics evaluated by magnetic resonance imaging. Pituitary 16(2), 158–167 (2013). https://​doi.​org/​10.​1007/​s11102-012-0395-7 CrossRefPubMed
37.
38.
Zurück zum Zitat G. Minniti, M.L. Jaffrain-Rea, V. Esposito, A. Santoro, G. Tamburrano, G. Cantore, Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr. Relat. Cancer 10(4), 611–619 (2003)CrossRefPubMed G. Minniti, M.L. Jaffrain-Rea, V. Esposito, A. Santoro, G. Tamburrano, G. Cantore, Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr. Relat. Cancer 10(4), 611–619 (2003)CrossRefPubMed
40.
Zurück zum Zitat A. Tamasauskas, K. Sinkunas, W. Draf, V. Deltuva, A. Matukevicius, D. Rastenyte, S. Vaitkus, Management of cerebrospinal fluid leak after surgical removal of pituitary adenomas. Medicina 44(4), 302–307 (2008)CrossRefPubMed A. Tamasauskas, K. Sinkunas, W. Draf, V. Deltuva, A. Matukevicius, D. Rastenyte, S. Vaitkus, Management of cerebrospinal fluid leak after surgical removal of pituitary adenomas. Medicina 44(4), 302–307 (2008)CrossRefPubMed
41.
Zurück zum Zitat C. Romero Adel, J.E. Nora, T.E. Topczewski, P.H. Aguiar, I. Alobid, E.F. Rodriguez, Cerebrospinal fluid fistula after endoscopic transsphenoidal surgery: experience in a spanish center. Arq. Neuropsiquiatr. 68(3), 414–417 (2010)CrossRefPubMed C. Romero Adel, J.E. Nora, T.E. Topczewski, P.H. Aguiar, I. Alobid, E.F. Rodriguez, Cerebrospinal fluid fistula after endoscopic transsphenoidal surgery: experience in a spanish center. Arq. Neuropsiquiatr. 68(3), 414–417 (2010)CrossRefPubMed
Metadaten
Titel
Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission
verfasst von
Marcelo Lemos Vieira da Cunha
Luis Alencar Biurrum Borba
Cesar Luiz Boguszewski
Publikationsdatum
20.02.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02227-2

Weitere Artikel der Ausgabe 1/2020

Endocrine 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.